Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

被引：33
作者：
Hartrampf, Philipp E. [1 ]
Weinzierl, Franz-Xaver [1 ]
Buck, Andreas K. [1 ]
Rowe, Steven P. [2 ]
Higuchi, Takahiro [1 ]
Seitz, Anna Katharina [3 ]
Kuebler, Hubert [3 ]
Schirbel, Andreas [1 ]
Essler, Markus [4 ]
Bundschuh, Ralph A. [4 ]
Werner, Rudolf A. [1 ]
机构：
[1] Univ Hosp Wuerzburg, Dept Nucl Med, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany
[2] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci Russell H Morgan, 601 N Caroline Str, Baltimore, MD USA
[3] Univ Hosp Wuerzburg, Dept Urol & Paediat Urol, Oberdurrbacherst 6, D-97080 Wurzburg, Germany
[4] Univ Hosp Bonn, Dept Nucl Med, Venusberg Campus 1, D-53127 Bonn, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2022年 / 49卷 / 09期
关键词：
PSMA I&T; PSMA-617; Prostate-specific membrane antigen; Prostate cancer; Radioligand therapy; Matched pair; MITOXANTRONE PLUS PREDNISONE; OPEN-LABEL; CABAZITAXEL;
D O I：
10.1007/s00259-022-05744-6
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Background Labelled with lutetium-177, the urea-based small molecules PSMA I&T and PSMA-617 are the two agents most frequently used for radioligand therapy (RLT) in patients with advanced metastatic castration-resistant and prostate-specific membrane antigen (PSMA) expressing prostate cancer (mCRPC). In this matched-pair analysis, we aimed to compare the toxicity and efficacy of both agents for PSMA-directed RLT. Materials and methods A total of 110 mCRPC patients from two centres were accrued, 55 individuals treated with [Lu-177]Lu-PSMA I&T, and a matched cohort of 55 patients treated with [Lu-177]Lu-PSMA-617. Matching criteria included age at the first cycle, Gleason score, prostate-specific antigen (PSA) values, and previous taxane-based chemotherapy. Using common terminology criteria for adverse events (CTCAE v. 5.0), toxicity profiles were investigated (including bone marrow and renal toxicity). Overall survival (OS) between both groups was compared. Results Toxicity assessment revealed grade III anaemia in a single patient (1.8%) for [Lu-177]Lu-PSMA I&T and five (9.1%) for [Lu-177]Lu-PSMA-617. In addition, one (1.9%) grade III thrombopenia for [Lu-177]Lu-PSMA-617 was recorded. Apart from that, no other grade III/IV toxicities were present. A median OS of 12 months for patients treated with [Lu-177]Lu-PSMA I&T did not differ significantly when compared to patients treated with [Lu-177]Lu-PSMA-617 (median OS, 13 months; P = 0.89). Conclusion In this matched-pair analysis of patients receiving one of the two agents most frequently applied for PSMA RLT, the rate of clinically relevant toxicities was low for both compounds. In addition, no relevant differences for OS were observed.
引用
收藏
页码：3269 / 3276
页数：8
相关论文
共 25 条
[1]   Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) [J].
Ahmadzadehfar, Hojjat ;
Rahbar, Kambiz ;
Baum, Richard P. ;
Seifert, Robert ;
Kessel, Katharina ;
Boegemann, Martin ;
Kulkarni, Harshad R. ;
Zhang, Jingjing ;
Gerke, Carolin ;
Fimmers, Rolf ;
Kratochwil, Clemens ;
Rathke, Hendrik ;
Ilhan, Harun ;
Maffey-Steffan, Johanna ;
Sathekge, Mike ;
Kabasakal, Levent ;
Osvaldo Garcia-Perez, Francisco ;
Kairemo, Kalevi ;
Maharaj, Masha ;
Paez, Diana ;
Virgolini, Irene .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (01) :113-122
[2]  
[Anonymous], 2017, Common terminology criteria for adverse events (CTCAE)
[3]  
Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
[4]   Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer [J].
Benesova, Martina ;
Schaefer, Martin ;
Bauder-Wuest, Ulrike ;
Afshar-Oromieh, Ali ;
Kratochwil, Clemens ;
Mier, Walter ;
Haberkorn, Uwe ;
Kopka, Klaus ;
Eder, Matthias .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :914-920
[5]   Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study [J].
Berthold, Dominik R. ;
Pond, Gregory R. ;
Soban, Freidele ;
de Wit, Ronald ;
Eisenberger, Mario ;
Tannock, Ian F. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :242-245
[6]   Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort [J].
Calais, Jeremie ;
Gafita, Andrei ;
Eiber, Matthias ;
Armstrong, Wesley R. ;
Gartmann, Jeannine ;
Thin, Pan ;
Nguyen, Kathleen ;
Lok, Vincent ;
Gosa, Laura ;
Grogan, Tristan ;
Esfandiari, Rouzbeh ;
Allen-Auerbach, Martin ;
Quon, Andrew ;
Bahri, Shadfar ;
Gupta, Pawan ;
Gardner, Linda ;
Ranganathan, David ;
Slavik, Roger ;
Dahlbom, Magnus ;
Herrmann, Ken ;
Delpassand, Ebrahim ;
Fendler, Wolfgang P. ;
Czernin, Johannes .
JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (10) :1440-1446
[7]   Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].
de Bono, Johann Sebastian ;
Oudard, Stephane ;
Ozguroglu, Mustafa ;
Hansen, Steinbjorn ;
Machiels, Jean-Pascal ;
Kocak, Ivo ;
Gravis, Gwenaelle ;
Bodrogi, Istvan ;
Mackenzie, Mary J. ;
Shen, Liji ;
Roessner, Martin ;
Gupta, Sunil ;
Sartor, A. Oliver .
LANCET, 2010, 376 (9747) :1147-1154
[8]  
Hartrampf PE, CANCERS, V2022
[9]   Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer [J].
Heck, Matthias M. ;
Tauber, Robert ;
Schwaiger, Sebastian ;
Retz, Margitta ;
D'Alessandria, Calogero ;
Maurer, Tobias ;
Gafita, Andrei ;
Wester, Hans-Juergen ;
Gschwend, Juergen E. ;
Weber, Wolfgang A. ;
Schwaiger, Markus ;
Knorr, Karina ;
Eiber, Matthias .
EUROPEAN UROLOGY, 2019, 75 (06) :920-926
[10]   [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial [J].
Hofman, Michael S. ;
Emmett, Louise ;
Sandhu, Shahneen ;
Iravani, Amir ;
Joshua, Anthony M. ;
Goh, Jeffrey C. ;
Pattison, David A. ;
Tan, Thean Hsiang ;
Kirkwood, Ian D. ;
Ng, Siobhan ;
Francis, Roslyn J. ;
Gedye, Craig ;
Rutherford, Natalie K. ;
Weickhardt, Andrew ;
Scott, Andrew M. ;
Lee, Sze-Ting ;
Kwan, Edmond M. ;
Azad, Arun A. ;
Ramdave, Shakher ;
Redfern, Andrew D. ;
Macdonald, William ;
Guminski, Alex ;
Hsiao, Edward ;
Chua, Wei ;
Lin, Peter ;
Zhang, Alison Y. ;
McJannett, Margaret M. ;
Stockler, Martin R. ;
Violet, John A. ;
Williams, Scott G. ;
Martin, Andrew J. ;
Davis, Ian D. .
LANCET, 2021, 397 (10276) :797-804
123